EWP
VKTX icon

Elevation Wealth Partners’s Viking Therapeutics VKTX Stock Holding History

Elevation Wealth Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86K Buy
99
+37
+60% +$1.2K ﹤0.01% 1077
2026
Q1 		$2.02K Hold
62
– – ﹤0.01% 909
2025
Q4 		$2.18K Hold
62
– – ﹤0.01% 778
2025
Q3 		$1.63K Hold
62
– – ﹤0.01% 682
2025
Q2 		$1.64K Hold
62
– – ﹤0.01% 432
2025
Q1 		$1.5K Buy
62
+12
+24% +$379 ﹤0.01% 435
2024
Q4 		$2.01K Hold
50
– – ﹤0.01% 438
2024
Q3 		$3.17K Hold
50
– – ﹤0.01% 411
2024
Q2 		$2.65K Hold
50
– – ﹤0.01% 435
2024
Q1 		$4.1K Hold
50
– – ﹤0.01% 399
2023
Q4 		$554 Hold
50
– – ﹤0.01% 412
2023
Q3 		$554 Buy
+50
New +$715 ﹤0.01% 310

Other funds holding VKTX

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Elevation Wealth Partners's VKTX Position: Q2 2026 in Review

Elevation Wealth Partners increased its Viking Therapeutics (VKTX) stake by 60% in Q2 2026, buying an estimated $1.2K and bringing the position to 99 shares worth $3.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1077.

Elevation Wealth Partners first reported a position in VKTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $4.1K in Q1 2024. 52 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Elevation Wealth Partners held 99 shares of Viking Therapeutics worth $3.86K as of Q2 2026.
  • Elevation Wealth Partners bought 37 Viking Therapeutics shares in Q2 2026, an estimated $1.2K.
  • Viking Therapeutics made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #1077 holding.
  • Elevation Wealth Partners first reported a position in Viking Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Elevation Wealth Partners's Viking Therapeutics position peaked at $4.1K in Q1 2024.
  • 52 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.